Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma
Open Access
- 16 July 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 113 (4), 616-625
- https://doi.org/10.1038/bjc.2015.237
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- First Axl inhibitor enters clinical trialsNature Biotechnology, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancerNature Genetics, 2012
- Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repairNature Genetics, 2012
- Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcomaBlood, 2010
- Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survivalProceedings of the National Academy of Sciences of the United States of America, 2009
- Gas6 and the Receptor Tyrosine Kinase Axl in Clear Cell Renal Cell CarcinomaPLOS ONE, 2009
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001